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Abstract
Background: People with Huntington’s disease (HD) often require tailored healthcare and support packages that 
develop as the disease progresses. The Client Service Receipt Inventory (CSRI) gathers retrospective 
information on service utilization. This study investigated the use of formal services and informal care as 
measured by the CSRI and explored associations between informal care, disease severity and functional ability 
as measured by the Unified Huntington’s Disease Rating Scale Total Motor Score (UHDRS-TMS) and functional 
scales.
Methods: All monitored longitudinal data from annual clinical assessments of UHDRS-TMS and functional 
assessments and CSRI collected under the auspices of the European Huntington’s Disease Network (EHDN) 
REGISTRY study between the years 2004 and 2009 were utilised in the analyses. Disease severity was reflected 
by UHDRS-TMS. Functional ability was measured using the UHDRS functional scales. CSRI data were analysed 
according to percentage use of individual formal services and total estimated hours per week of informal care. 
Regression analyses were conducted to identify any associations between disease severity, functional ability 
and hours of informal care.
Results: 451 HD patients (212 female; 239 male) completed one visit; 105 patients (54 females; 51 males) 
completed two visits and 47 patients (20 females; 27 males) completed three visits in total over the 5 year 
period. The mean time between visits was 1.2 years. At visit one, 74% of the participants reported being in 
receipt of at least one formal hospital-based service in the previous six months, and 89% reported receipt of 
formal primary and community care services. In contrast, at the third visit, 62% of people had used hospital 
based services and 94% formal community based services in the previous six months. Fifty % of individuals 
required some form of informal care in the home at visit 1; this increased to 68% at visits 2 and 3. The mean 
(SD) estimated weekly total informal care hours at visits 1, 2 and 3 were 32.8 (49.4); 21.6 (53.6) and 21.3 (62.4) 
respectively. Only the scores on the Functional Assessment Scale (FAS) accounted for the variance in the 
weekly total informal care hours at each visit.
Conclusions: Although it must be acknowledged that service use is supply driven, most HD patients across 
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Europe surveyed as part of this study were in receipt of formal primary and community care services and to a 
lesser extent formal hospital based services. There was however a large reliance on informal care in the home. 
The FAS appear to have predictive value on informal care requirements and may have utility in facilitating pro-
active service provision and in particular when managing carer burden in this population.
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Introduction:
Huntington’s disease (HD) is an inherited, neurodegenerative disease resulting in clinical symptoms of 
progressive movement disorder, cognitive defects and behavioural changes that ultimately affects a person’s 
ability to participate independently in activities of daily living, work and community. With an approximately 20 
year time course from symptom onset, death usually results from complications of falls, dysphagia, or 
aspiration [1] . Over the course of the disease, the person with HD will require a range of generic and specialist 
professional services [2] [3] and flexible, co-ordinated practical and psychological support [4] depending on the 
stage of condition and that person’s functional status. In the earlier stages of the disease, healthcare focuses on 
maintaining and/or preventing decline in mental and physical functioning. Later on in the disease, care is 
usually more supportive in nature. Although cognition and behavioural problems have a greater incidence in 
people requiring full time care, advanced motor impairment has been found to be the greatest predictor of 
nursing home placement in HD patients [5] .
Successful care will usually involve the efforts of a multi-disciplinary team working closely with the family to 
optimize quality of life over the life span of the disease [6] [7] [8] . Here, care of the person with HD should be 
person-centred with the person with HD and their immediate family linked to the multi-disciplinary team for 
appropriate medical, health and social care so as to maximize function and prepare for future challenges [3] . 
Health professionals involved in the care of the person with HD may include the General practitioner, 
Psychiatrist, Neurologist, Geneticist, Psychologist, Social Worker, Speech Therapist, Occupational Therapist, 
Physiotherapist and Community and/or specialist nurse [6] . Social services and home help or nursing may also 
be crucial. The diverse nature of symptoms seen in different individuals with HD, over time and involving 
various services make care planning and service development complex [6] . There have been suggestions that 
due to these complexities, in many cases, care needs are unmet [6] [9] both in the earlier [10] and more 
palliative stages of the disease [8] . The complexity in provision of care requirements also often results in the 
family members i.e. informal carers undertaking the overall responsibility for care [11] .
Informal care is that which is delivered by non-expert carers who are usually family or friends, may range from 
full time care from person who lives with the HD patient to intermittent input from someone living elsewhere. 
Informal care will vary according to the needs of the person with HD and may range from looking after all 
personal needs to help with shopping and care of home on less frequent basis. Informal carers are often 
required to provide both psychological and practical support over extended periods of time [4] and the impact 
on their quality of life as a result of supporting the person with HD at home should certainly not be 
underestimated [12] [13] . Informal care is also not subject to audit or regulation and may not always be 
optimal for the person with HD and for the person providing that care.
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To be able to ensure that care needs are met, appropriate and informed service planning is required. The first 
step in this process is to quantify actual use of formal healthcare resources and the balance between formal 
care services and informal care use.
Knowledge of such data has the potential to facilitate appropriate planning and resource allocation in line with 
standards of excellence for chronic conditions management. In the United Kingdom, a National Service 
Framework for people with Long Term Neurological Conditions (LTNCs) sets out quality requirements for care. 
These include prioritisation for personal care and support with appropriate support for family and carers and 
access to appropriate aids and home adaptations to promote living at home to facilitate living at home for as 
long as is able with as high a quality of life as possible [14] . In order to evaluate whether such quality 
standards are being met, current service use needs to be described. There is an on-going programme of study 
evaluating service use in rare LTNCs (RESULT study) (http://www.ltnc.org.uk/research_files/RESULT_study.html) 
for this specific purpose but to date no data is available in published literature of specific service receipt in HD 
patients.
The Client Service Receipt Inventory (CSRI) questionnaire was developed [15] [16] specifically to provide 
information on service utilisation and ultimately inform service delivery by collecting retrospective information 
on service related issues. It is an established tool and has been used in a range of research studies including 
mental health outreach services, community nursing services and community care of older people and people 
with challenging behaviour [16] [17] . The questionnaire schedule is designed for interviewer/researcher 
administration with the person receiving the services assisted by their main carer as required. The retrospective 
period is fixed according to the population being investigated and according to the specific aims of the 
research. It therefore varies by the research design in question and allows capture of information on rarer 
services that may be received in a set time period whilst not being subject to the problems of recall bias. The 
service receipt section is the core of the CSRI [16] ; for each service type, the number and average duration of 
contacts is recorded and used to summarise particular care packages, illustrate the variety of services used and 
in particular determine how resources are allocated. HD patients at different stages of the disease will have 
particular health care needs requiring specific combinations of health services and this will have associated 
service planning implications. Clear assessment of disease impact and severity alongside healthcare resource 
use is a key requirement for resource planning and predicting future care needs.
Disease severity is routinely quantified using the Unified Huntington’s Disease Rating Scales (UHDRS) [18] [19] , 
a disease specific rating system that is used to assess the severity of disease. With the UHDRS, specific 
domains of clinical performance namely motor ability, cognition and behaviour are assessed. The motor rating 
involves 31 questions representing oculomotor, speech, motor, and gait findings rated on a 0- to 4-point scale 
(4 most impaired). The cognitive assessments incorporate verbal fluency, ability to pair numbers with figures 
and selective attention whilst the behavioural assessment considers severity and frequency of mood, anxiety, 
aggression, psychosis, and other behavioural abnormalities. The UHDRS functional components comprise three 
ordinal components, namely the functional assessment scale (FAS) (an activities of daily living checklist with 
range 0 to 25), the Independence scale (IS) (range 10-100), and the Total Functional Capacity (TFC) (range 0 to 
13). Scores on the TFC can further represent five stages in the neurodegenerative disease process: stage I 
represents scores from 13-11; stage II, scores of 10-7; stage III, scores of 6-3; stage IV, scores of 2-1; and stage 
V, a score of 0. The independence scale has a range of 10 to 100 units and evaluates dependence on care from 
total care required to no special care needed.
The aim of this study was to investigate the use of formal and informal care services as recorded using 
retrospective CSRI data and to investigate any associations between use of care, disease severity and 
functional ability as measured by the UHDRS motor and functional scales.
In these analyses, we specifically sought to identify, a) what care (both formal services and informal care) HD 
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patients currently use and b) whether there were any specific factors associated with the estimated amount of 
informal care required. To our knowledge such data has not previously been presented for a cohort of HD 
patients; we suggest that availability of such data in a cohort of HD patients from a cross-section of European 
countries is of use in quantifying and ultimately improving planning of service provision for HD patients.
Methods and materials:
REGISTRY is a multi-centre, multi-national observational study with no experimental intervention. REGISTRY is 
managed by the European Huntington’s Disease Network (EHDN) and aims to build up an electronic database of 
patients with HD and their relatives. The main component of the ‘ REGISTRY ‘ study is the storage of 
anonymous medical data on an electronic database. One of the aims of REGISTRY is to obtain natural history 
data on an annual basis over an extended time period on a wide spectrum of individuals affected by HD to 
facilitate data mining studies.
For the purposes of the analyses presented here, the monitored data of demography, CAG repeat, estimated 
age of onset, disease severity and functional ability as measured by the Unified Huntington’s Disease Rating 
Scale total motor score (UHDRS-TMS) and functional scales in combination with the CSRI has been utilised for 
data mining. Data was collected according to the standard REGISTRY protocol [20]. The EHDN REGISTRY CSRI 
refers to the immediate six month retrospective period. It records details on use of hospital and residential 
services; primary and community care services; investigations and diagnostic tests; aids or devices; adaptations 
to the home; informal care; average loss of income per week; journeys undertaken and occupation.
Data were analysed descriptively for demographics and according to percentage use of individual services and 
aggregates of service receipt namely 1) total number of individual formal services received 2) aggregates of 
hospital services (inpatient and outpatient) and primary and community care and 3) the carer or patient 
estimated total informal care hours (personal, help inside the home, help outside the home and other) as 
recorded by the CSRI. As the focus on our investigations was to establish service use frequencies in the first 
instance and not costs per se, we do not report on investigations and diagnostic tests, average loss of income 
per week; journeys undertaken and occupation in these analyses.
In order to identify specific factors associated with receipt of services at each visit, we utilised linear regression 
with estimated hours of informal care as the dependant variable and the measures of disease severity and 
functional ability as the independent variables. All analyses were conducted using PASW version 18 Release 
18.0.2 April 2010.
Results
Demographic and Descriptive data:
CSRI data for 451 HD patients (212 female; 239 male) was available for visit one (at enrolment to the study) of 
this observational study. Completed CSRI data for 105 (54 females; 51 males) and 47 (20 females; 27 males) 
HD patients was available for visits two and three respectively. The mean time between visits was 1.2 years. 
Countries represented were Austria (8.6%); Germany (33.7%); Italy (15.3%); Norway (3.3%); Poland (18.4%); 
Portugal (2.9%); Spain (10.6%); Switzerland (0.9%) and United Kingdom (6.2%).
Mean (SD) estimated age of onset was 41.8 (12.8) years and age at visit 1 was 49.5 (13.1). Median (range) CAG 
repeat length was 45 (35-89). Median (range) scores at visit 1 on UHDRS-TMS, Functional assessment scale 
(FAS), Total Functional Capacity (TFC) and Independence Scale were 34 (0-106); 20 (0-25); 8 (0-13) and 80 (10-
100) respectively. At Visit 2, median (range) scores on UHDRS-TMS, Functional assessment scale (FAS), Total 
Functional Capacity (TFC) and Independence Scale were 37 (0-111); 16 (0-25); 7 (0-13) and 75 (10-100) 
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respectively.At Visit 3, median (range) scores on UHDRS-TMS, Functional assessment scale (FAS), Total 
Functional Capacity (TFC) and Independence Scale were 43 (0-97); 13 (0-25); 5 (0-13) and 70 (25-100) 
respectively. It is important to note the altered proportional representation of people with HD at each stage of 
the disease for each visit. At visit 1, most participants (n=153; 34%) were at Stage 1 of the disease; by visit 3 
most participants (n=58; 61%) were at either stage 3 or 4 of the disease. Table 1 gives details of percentage of 
the sample at each stage of the disease for each visit.
Table 1: Frequencies and valid percentages of HD patients at each visit stratified according to 
stage of disease (represented by TFC scores)
TFC stage of 
disease
Number (%) of total sample 
at visit 1 at each stage of the 
disease
Number (%) of total sample 
at visit 2 at each stage of the 
disease
Number (%) of total sample 
at visit 3 at each stage of the 
disease
1 (TFC 11-13) 153 (34%) 59 (27%) 18 (19%)
2 (TFC 7-10) 125 (28%) 57 (25%) 18 (19%)
3 (TFC (3-6) 119 (26%) 74 (33%) 36 (38%)
4 (TFC 1-2) 47 (10%) 31 (14%) 22 (23%)
5 (TFC 0) 7 (2%) 3 (1%) 1 (1%)
Receipt of services:
At visit 1, 335 of the 451 participants were in receipt of at least one formal hospital based service and 401 
(89%) were in receipt of primary and community care services. In contrast, 94% of people used community 
based services at visit 3 and 62% used hospital based services. Fifty percent of individuals reported use of 
informal care in the home at visit 1; this increased to 68% at visits 2 and 3 (see Table 2).The increase in service 
use frequencies and care hours reported in visits 2 and 3 do however need to be considered in light of the 
greater proportion of people in stages 3 and 4 of the disease at visit 3 compared to those at visit 1 (see Table 1).
Inpatient hospital service use increased dramatically over visits and outpatient service use decreased. 
Percentage of people in receipt of physiotherapy and speech and language therapy services increased at each 
visit; whilst social worker involvement remained relatively constant. Home help use increased over time. 
Notable is that occupational therapy, dentistry and other allied health professional services was not 
independently recorded in the version of CSRI used here and may well be under-reported in this situation. There 
was additionally no mention of key-worker involvement.
Table 2: Frequencies and valid percentages of HD patients receiving care services at each visit
Service receipt for HD 
patients
Number (%) of total 
sample receiving 
services at visit 1 
(n=451)
Number (%) of total 
sample receiving 
services at visit 2 
(n=105)
Number (valid %) of total 
sample receiving 
services at visit 3 (n=47)
Hospital services 
Inpatient 
Outpatient
335 (75%) 
110 (24%) 
300 (69%)
73 (70%) 
58 (64%) 
17 (16%)
29 (62%) 
28 (60%) 
5 (11%)
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Primary and Community 
care
GP 
Neurologist 
Other doctor 
Physiotherapist 
Social Worker 
Nurse 
Speech Therapist 
Home-help 
Other (Occupational 
therapy, Dentistry; 
Chiropractor)
401 (89%) 
333 (74%) 
170 (38%) 
73 (16%) 
91 (20%) 
45 (10%) 
30 (7%) 
58 (13%) 
51 (11%) 
42 (9%)
89 (85%) 
68 (65%) 
35 (33%) 
14 (14%) 
31 (30%) 
14 (13%) 
15 (14%) 
18 (17%) 
15 (14%) 
15 (14%)
44 (94%) 
36 (77%) 
25 (53%) 
6 (13%) 
21 (45%) 
4 (9%) 
4 (9%) 
13 (28%) 
9 (19%) 
7 (15%)
Informal Care 
Personal care 
Help inside the home 
Help outside the home 
Other
224 (50%) 
130 (29%) 
195 (43%) 
170 (38%) 
36 (8%)
71 (68%) 
14 (39%) 
63 (60%) 
54 (51%) 
14 (13%)
32 (68%) 
22 (47%) 
29 (62%) 
25 (53%) 
7 (15%)
Use of aids and adaptations:
The use of wheelchairs increased over each visit, but all other appliance use remained fairly constant (see Table 
3). Crutches and frames were used fairly infrequently whilst home adaptation (bathroom, shower and toilet) was 
a slightly more frequent occurrence.
Table 3: Frequencies and valid percentages of HD patients using aids and adaptations in the home 
at each visit
Aids and Adaptations in 
the home
Number (%) of total 
sample at visit 1 (n=451)
Number (%) of total 
sample at visit 2 (n=105)
Number (valid %) of total 
sample at visit 3 (n=47)
Aids or devices
Wheelchairs 27 (6%) 17 (16%) 17 (15%)
Crutches 10 (2%) 1 (1%) 2 (4%)
Walking frames/ Rollators 17 (4%) 7 (7%) 1 (2%)
Other 17 (4%) 5 (4%) 5 (11%)
Adaptations to the 
home
Stair lift 11 (2%) 4 (4%) 1 (4%)
Shower/bath relocation 26 (6%) 13 (12%) 11 (23%)
Toilet relocation 17 (4%) 7 (7%) 4 (9%)
Redesign kitchen 7 (2%) 3 (3%) 1 (2%)
Medicalised Bed 8 (2%) 5 (5%) 1 (2%)
Concrete ramp 3 (1%) 3 (3%) 0 (0%)
Other (Move home) 31 (7%) 14 (13%) 2 (4%)
Aggregates of Service Use:
The mean (SD) estimated weekly total informal care hours at visits 1, 2 and 3 were 32.8 (49.4); 21.6 (53.6) and 
21.3 (62.4) respectively (see Table 3). Although the mean reported informal care hours were less at each visit; 
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the mean number of informal care services used appeared to increase between visits 1 and 3. Mean number of 
formal primary and community services used (and percentages of individual services) also appeared to increase 
over time whilst formal hospital based services reduced over time. This is consistent with what was seen in 
terms of percentages of HD patients using different services (see Table 2).
Table 4: Aggregates of service use for each visit
Mean (SD); range 
of total individual 
formal service 
receipt
Mean (SD); 
range of number 
of hospital 
based services 
used
Mean (SD); range of 
number of primary 
and community care 
services used
Mean (SD); 
range of number 
of informal care 
services used
Mean (SD) 
informal 
care hours
Visit 1 
(n=451)
3.1 (1.8); 0-9 1.1 (0.9); 0-5 2.0 (1.4); 0-7 1.2 (1.4); 0-4 32.7 (49.4)
Visit 2 
(n=105)
3.2 (2.2); 0-10 1.1 (1.0); 0-4 2.1 (1.5); 0-7 1.6 (1.4); 0-4 21.6 (53.6)
Visit 3 
(n=47)
3.5 (1.7); 0-10 0.8 (0.9); 0-4 2.6 (1.5); 0-8 1.8 (1.4); 0-4 21.3 (62.4)
Predictors of informal care requirements:
Only the scores on the FAS accounted for the variance in the weekly total informal care hours at visit 1 (see 
Table 4). This remained a constant pattern over time. At Visit 2, the Functional Assessment Scale accounted for 
9 % of the variance in hours of informal care (adjusted R 2 8.6%; SE 59.9; F7.8 p<0.007) (excluded variables: 
TFC, UHDRS-TMS and Independence Scale). At Visit 3, the Functional Assessment Scale accounted for 33 % of 
the variance in hours of informal care (adjusted R2 30%; SE 25.7; F 13.6; p<0.001) (excluded variables: TFC, 
UHDRS-TMS and Independence Scale).
Table 5: Linear regression on estimated hours of informal care at Visit 1
Independent variables Standardized coefficients t Significance
Constant
Functional Assessment Scale -0.428 -3.423 0.000
Adjusted R 2 0.181 ; SE 34.186; F 88.784; p< 0.0001; dependant variable weekly total informal care hours
Discussion
Consideration of service use data reflecting current utilisation in the included sample is an important first step 
in the provision of high quality care. This study employed the CSRI to gather information about types and 
quantities of resources used by HD patients. We did not attempt to provide any indication of the monetary cost 
of service utilisation. This is partly because unit costs will vary according to country and hence in some cases 
will be applied only to small numbers, but mainly because such “cost of illness” information would not 
necessarily be optimal in informing policy decisions. Quantifying costs of services (rather than demonstrating 
frequencies of resource use as we have done) would be more appropriate in the context of an economic 
evaluation of a specific intervention [21] .
Most HD patients surveyed as part of this study were in receipt of some formal primary and community care 
services and to a lesser extent hospital based services. Trends in service provision over time may be inferred 
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from the longitudinal data presented but it is important to acknowledge that some bias may be introduced to 
the study simply as result of being a research participant in a large scale observational study such as REGISTRY. 
In addition, as the numbers of participants decrease with each visit, there is an associated change in 
proportional representation of people at each stage of the disease. We cannot infer that the cohort is 
deteriorating over time resulting in an increased service use; the changes in service use may simply be skewed 
by this proportional change in individuals at each stage of the disease. We therefore suggest that a general 
impression of service receipt is best judged at visit 1 (study entry) where any effect on reporting rates and the 
bias introduced by the annual visit or the altering proportional representation of the sample at each visit is 
limited.
At enrolment to the REGISTRY study, 89% of HD patients assessed in this data mining study were in receipt of 
at least 1 form of primary or community care service. It is not possible to establish any measure of how 
integrated these services were and additionally there was no clear indication of key worker or occupational 
therapy involvement as this was not part of the standard questions employed in the REGISTRY CSRI. Social 
worker and nurse involvement was fairly minimal and use of formal home help was reported in only 11% of 
participants in this cohort. Approximately 1/5th of participants were in receipt of physiotherapy services at the 
first visit and the use of crutches and walking aids was infrequent. Such infrequent use of walking aids is 
congruent with suggestions in the literature that physiotherapists do not recommend routine use of aids as 
choreic movement and cognitive impairment may influence safe use of walking aids in HD patients [22] .
When considering service use frequencies, it is useful to compare with other groups of patients with 
neurodegenerative diseases. A report (published in 2000) of community services for people with Multiple 
Sclerosis (MS) (n=150) living in the United Kingdom found that at that time of 45% of people with MS did not 
receive any form of community services [23] . The remaining 55 % of people with MS were in receipt of a range 
of services including home help (20%), occupational therapy, physiotherapy (23%), social work (10%) and 
district nursing (17%). Twenty-seven % of participants had bath or shower adaptations in place. Those people 
who had no home adaptations (42%) in place were also not in receipt of any services. There appeared to be a 
substantial unmet need for people with MS in terms of community care with little change since the beginning of 
the previous decade [23] . The authors advocated the need for integrated, co-ordinated and multi-agency 
community service for people with MS. Of concern in our data (in light of the suggested relationship between 
lack of integrated community care and lack of home adaptation [23] ) are the seemingly low levels of home 
adaptations in this group of people. Adaptations of the home were in place in less than a quarter of HD patients 
included in this study. Although this may be due to the fact that the minority of those surveyed in this study (at 
visit 1) were in the late stages of the disease and also that our data may not necessarily be representative of 
the HD population, further investigation is warranted.
This analysis is not without limitations. It is important to acknowledge that the descriptive data presented here 
is specific to this fairly small sample (to date REGISTRY has enrolled over 6000 participants so our data is only 
reflective of approximately 8 % of the HD population). Additionally, almost all of the participants enrolled in 
REGISTRY are able to reach a HD clinic for annual assessments and on review it was clear that only a small 
proportion of our sample were in the late stages of the disease. It is therefore likely that the data presented 
here is not representative of the most severely affected HD patients.
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There will also be substantial differences across countries in terms of the support in the community that is 
available (i.e. service use is supply driven) and additionally there will clearly be inherent differences in health 
care systems between various European countries. The specific role that each member of the health care team 
may vary according to geographical region and this level of detail is not captured by the REGISTRY CSRI. 
Furthermore, there was no distinction between HD or non-HD related service use. It is difficult to say how much 
of the service use reported here is because of HD and there are many other factors which may lead a person to 
requiring formal health care services.
Our data suggests a large reliance on informal care in the home in this group studied. At the first visit, half of all 
the HD patients in this study were in receipt of some manner of informal care in the home. It seems that 
informal carers will continue in this function up the very limits of their capacity and discussions with family 
members have highlighted some contributing factors. HD is seen as a family problem that ought to be managed 
by the involved family. Families trying to use available formal services encounter the problem of frequently 
changing care-givers and irregularity and restrictions in terms of the hours that the services can be provided. 
Such irregularity and frequent change is clearly not in agreement with the nature of HD and the person affected 
with HD. The HD patient is highly dependent on regularity and familiarity, making provision of community based 
care very challenging. Other studies of people with complex disability have suggested that where community 
care is limited, the burden of care often falls on the family and informal carers [24] [25] . Carer burden in this 
community should consequently be carefully considered by the healthcare team and where appropriate 
additional carer support should be provided. We suggest that use of routine rating scales employed in the 
clinical assessment may have some potential to identify high risk families where the informal care requirements 
are high. From the data presented here, it is clear that the TFC had no predictive value on service receipt or on 
informal care hours whilst the UHDRS functional assessment scale (FAS) had reasonable predictive value on this 
variable. When individuals present with lower scores on the FAS, they appear to have higher informal care 
requirements and carer burden may additionally be higher. The FAS is an activity of daily living checklist with 
range from 0 to 25. The components of the checklist represent multiple domains of function including aspects of 
employment, finances, shopping, driving, housework, supervising children, personal activities of daily living, 
mobility and housework. This wide representation of domains may be one reason why the FAS seems to have 
better predictive value than TFC which is reflective of fewer domains. In this study, the FAS accounted for 30% 
of the variance in informal care hours by visit 3. In-depth investigation of suitable clinical scales and potential 
weighting of components may improve predictive value. Such targeted assessments could aid clinicians, 
funding agencies and policy makers in appropriate service planning and provision of co-ordinated care for HD 
patients.
The data presented here is suggestive of the need for integrated and proactive care provision that addresses 
the requirements of the HD patients and their carers. It is clear that a method or a system to aid identification 
of factors indicative of the need for referral to formal services is required. Studies of the emotional experiences 
of family carers in HD and supportive care needs for people living with the disease highlight the high levels of 
emotional stress that can be associated with HD [4] [13] . It is important that care is individualised and specific 
to the needs of the HD patient. Availability of a consistent team of support workers and appropriate community 
support and carer support may facilitate management of the varying needs over time and prioritise referrals to 
services as needed [26] [4] . The high level of informal care reported here indicates that such a model of care is 
not yet systematically provided in the HD community and is an area that is in need of attention.
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APPENDIX 1
Contributors (study sites and individual members at the study sites) from the 
European Huntington’s disease Network to the data collected for analysis in this 
study are listed in alphabetical order by country below.
Contributors (study sites and individual members at the study sites) from the European Huntington’s disease 
Network to the data collected for analysis in this study are listed in alphabetical order by country below. 
AUSTRIA
Graz (LKH Graz, Abteilung für Psychiatrie): Raphael M. Bonelli; Brigitte Herranhof;  Anna Holl (formerly Hödl); 
Hans-Peter Kapfhammer; Michael Koppitz; Markus Magnet; Daniela Otti; Annamaria Painold; Karin Reisinger; 
Monika Scheibl; Karen Hecht; Sabine Lilek; Nicole Müller; Helmut Schöggl; Jasmin Ullah
Innsbruck (Universitätsklinik Innsbruck, Neurologie): Florian Brugger; Caroline Hepperger; Anna Hotter; Philipp 
Mahlknecht; Michael Nocker; Klaus Seppi; Gregor Wenning; Lisa Buratti; Eva-Maria Hametner; Christiane Holas; 
Anna Hussl; Katharina Mair; Werner Poewe; Elisabeth Wolf;  Anja Zangerl; Eva-Maria Braunwarth 
GERMANY
Aachen (Universitätsklinikum Aachen, Neurologische Klinik): Christoph Michael Kosinski; Daniela Probst; 
Christian Sass; Johannes  Schiefer; Christiane Schlangen; Cornelius J. Werner
Dinslaken (Reha Zentrum in Dinslaken im Gesundheitszentrums Lang): Herwig Lange
Dresden (Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik 
für Neurologie):  Andrea Friedrich; Ulrike Hunger; Matthias Löhle; Simone Schmidt;  Alexander Storch; Annett 
Wolz; Martin Wolz
Freiburg (Universitätsklinik Freiburg, Neurologie): Johann Lambeck, Birgit Zucker
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Hamburg (Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie): Kai Boelmans; Christos 
Ganos; Ute Hidding; Alexander Münchau; Michael Orth; Jenny Schmalfeld; Lars Stubbe; Simone Zittel
Heiligenhafen (Psychatrium Heiligenhafen): Walburgis Heinicke
Marburg KPP (Klinik für Psychiatrie und Psychotherapie Marburg-Süd): Bernhard Longinus
Marburg Uni (Universität Marburg, Neurologie): Jens Carsten Möller; Ida Rissling
München (Huntington-Ambulanz im Neuro-Kopfzentrum - Klinikum rechts der Isar der Neurologischen Klinik und 
Poliklinik der Technischen Universität München): Alexander Peinemann; Michael Städtler; Adolf Weindl
Münster (Universitätsklinikum Münster, Klinik und Poliklinik für Neurologie): Natalie Bechtel; Heike Beckmann; 
Stefan Bohlen; Eva Hölzner; Herwig Lange; Ralf Reilmann; Stefanie Rohm, Silke Rumpf ; Sigrun Schepers
Taufkirchen (Isar-Amper-Klinikum - Klinik Taufkirchen (Vils)): Antonie Beister; Matthias Dose; Kathrin Hammer; 
Janina Kieni; Gabriele Leythaeuser; Ralf Marquard; Tina Raab; Sven Richter; Amina Selimbegovic-Turkovic; 
Caroline Schrenk; Michele Schuierer; Alexandra Wiedemann
Ulm (Universitätsklinikum Ulm, Neurologie): Andrea Buck; Julia Connemann; Daniel Ecker; Carolin Eschenbach; 
Christine Held; Bernhard Landwehrmeyer; Franziska Lezius; Solveig Nepper; Anke Niess; Michael Orth, Sigurd 
Süßmuth, Sonja Trautmann; Patrick Weydt 
ITALY
Bologna (Università di Bologna, Dipartimento di Scienze Neuroloche - Clinica Neurologica): Sabrina Capellari; 
Pietro Cortelli; Roberto Gallasi; Roberto Poda; Giovanni Rizzo; Cesa Scaglione
Florence (Neurologia I- Unita' di Neurogenetica Departimento di Neurologia e Psichiatria, Universita' di Firenze): 
Elisabetta Bertini; Elena Ghelli, Claudia Mechi; Marco Paganini; Silvia Piacentini; Silvia Pradella; Anna Maria 
Romoli; Sandro Sorbi
Milan (Fondazione IRCCS Istituto Neurologico C. Besta, Milan):   Alberto Albanese; Stefano Di Donato; Cinzia 
Gellera; Silvia Genitrini; Caterina Mariotti; Daniela Monza; Lorenzo Nanetti; Domina Paridi; Paola Soliveri; Chiara 
Tomasello
Naples (Azienda Ospedaliera Universitaria Federico II - Dipartimento di Scienze Neurologiche): Giuseppe De 
Michele; Di Maio Luigi; Carlo Rinaldi; Cinzia Valeria Russo, Elena Salvatore; Tecla Tucci
Pozzilli (Neurogenetics Unit – IRCCS Neuromed): Milena Canella; Valentina Codella, Francesca De Gregorio, 
Nunzia De Nicola, Tiziana Martino; Mariella Simonelli; Ferdinando Squitieri
Rome (Istituto di Neurobiologia e Medicina Molecolare CNR/ Istituto di Neurologia, Dipartimento di 
Neuroscienze/ CNR Istituto di Scienze e Tecnologie della Cognizione): Anna Rita Bentivoglio; Alfonso Fasano; 
Marina Frontali; Arianna Guidubaldi; Tamara Ialongo; Gioia Jacopini; Giovanna Loria; Carla Piano; Silvia Romano; 
Francesco Soleti; Maria Spadaro; Paola Zinzi 
NORWAY
Oslo University Hospital (Rikshospitalet, Dept. of Medical Genetics and Dep. of Neurology): Arvid Heiberg; 
Marleen R van Walsem, Jan Frich; Raghild Wehus; Olaf Aaserud; Nancy Borgerød
Oslo University Hospital (Ulleval, Dept of Medical Genetics and Department): Kathrine Bjørgo; Madelein 
Fannemel; Per Gørvell; Eirin Lorentzen; Susana Pro Koivisto; Lars Retterstøl; Torborg Overland; Bodil Stokke
Trondheim (St. Olavs Hospital): Inga Bjørnevoll; Sigrid Botne Sando 
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POLAND
Gdansk (Specialistic Hospital, Gdansk Zaspa): Emilia Sitek; Jaroslaw Slawek; Witold Soltan.
Katowice (Silesian Medical University Katowice): Magdalena Boczarska-Jedynak; Barbara Jasinska-Myga; Gregorz 
Opala.
Krakow (Krakowska Akademia Neurologii): Krzysztof Banaszkiewicz; Andrzej Szczudlik; Monika Rudzińska; 
Magdalena Wójcik; Malgorzata Krawczyk.
Poznan (Medical University of Poznań): Anna Bryl; Anna Ciesielska; Aneta Klimberg; Jerzy Marcinkowski; Justyna 
Sempołowicz; Daniel Zielonka
Warsaw-MU (Medical University of Warsaw, Neurology): Piotr Janik; Anna Kalbarczyk; Hubert Kwiecinski; 
Zygmunt Jamrozik.
Warsaw-IPiN (Institute of Psychiatry and Neurology Dep. of Genetics, Dep. of Neurology): Jakub Antczak; 
Katarzyna Jachinska; Maria Rakowicz; Przemyslaw Richter; Danuta Ryglewicz; Grzegorz Witkowski; Elzbieta 
Zdzienicka; Jacek Zaremba. 
PORTUGAL
Lisbon-Santa Maria (Neurological Clinical Research Unit, Instituto de Medicina Molecular): Miguel Coelho; Leonor 
Guedes; Joaquim J Ferreira; Tiago Mendes; Tiago Mestre; Anabela Valadas.
Lisbon-Fernando Fonseca (Hospital Fernando Fonseca E.P.E., Serviço de Neurologia): Cristina Costa;  Ângela 
Timóteo.
Porto-Santo António (Hospital Geral de Santo António): Sara Cavaco; Joana Damásio; Marina Magalhães
Porto-São João (Hospital São João, E.P.E.): Miguel Gago; Carolina Garrett; Maria Rosália Guerra. 
SPAIN
Badajoz (Hospital Infanta Cristina): Carmen Durán Herrera; Patrocinio Moreno Garcia
Granada (Hospital Universitario San Cecilio, Neurología): Francisco Barrero; Blas Morales
Burgos (Servicio de Neurología Hospital General Yagüe): Esther Cubo; Natividad Mariscal; Jesús Sánchez
Madrid-Clinico (Hospital Clínico Universitario San Carlos): Rocío García-Ramos García; Purificacion Pin Quiroga; 
Clara Villanueva
Madrid RYC (Hospital Ramón y Cajal, Neurología): Mónica Bascuñana; Marta Fatás Ventura; Guillermo García 
Ribas; Justo García de Yébenes; José Luis López – Sendón Moreno, Patricia Trigo Cubillo
Madrid FJD (Madrid-Fundación Jiménez Díaz): Pedro J García Ruíz, Asunción Martínez-Descals, María José Saiz 
Artiga; Vicenta Sánchez
Barcelona-Hospital Mútua de Terrassa : Miquel Aguilar Barbera; Dolors Badenes Guia; Laura Casas Hernanz ; 
Judit López Catena; Ana Rojo Sebastián, Pilar Quiléz Ferrer; Gemma Tome Carruesco
Barcelona-Bellvitge (Hospital Universitari de Bellvitge): Jordi Bas; Núria Busquets; Matilde Calopa
Palma (Hospital Son Dureta): Aranzazú Gorospe; Inés Legarda; Penelope Navas Arques; María José Torres 
Rodríguez, Barbara Vives
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Sevilla (Hospital Virgen Macarena): Jose Manuel Garcia Moreno; José Chacón Peña; Luminita Dinca Avarvarei; 
Antonio Martín Bastida; Maria Fernández Recio; Luis Redondo Vergé; Violeta Sánchez Sánchez 
SWITZERLAND
Bern: Jean-Marc Burgunder; Yvonne Burgunder (Neurologische Klinik des Inselspitals); ; Alain Kaelin; 
Irene Romero; Michael Schüpbach; Sabine Weber Zaugg (Zentrum für Bewegungsstörungen, Neurologische 
Klinik und Poliklinik) 
UNITED KINGDOM
Aberdeen (NHS Grampian, Clinical Genetics Centre): Roisin Jack; Kirsty Matheson; Zosia Miedzybrodzka; Daniela 
Rae; Sheila Simpson; Fiona Summers; Alexandra Ure
Cardiff (The Institute of Medical Genetics, University Hospital of Wales): Monica Busse, Stephen Dunnett, 
Catherine Clenaghan, Ruth Fullham, Sarah Hunt, Lesley Jones, Una Jones, Hanan Khalil, Sara Minster, Michael 
Owen, Kathleen Price, Jenny Townshill, Anne Rosser.
Edinburgh (Molecular Medicine Centre, Western General Hospital, Department of Clinical Genetics): Paul A. De 
Sousa; Maureen Edwards; Teresa Hughes (Scottish Huntington´s Association); Marie McGill; Pauline Pearson; 
Mary Porteous; Paul Smith (Scottish Huntington´s Association); Adam Zeman
Leicester (Leicestershire Partnership Trust, Mill Lodge): Colin Bourne; Carole Clayton; Heather Dipple; Jackie 
Clapton, Janet Grant; Diana Gross; Caroline Hallam; Julia Middleton; Ann Murch, Dawn Patino
London (St. Georges-Hospital): Michael Patton, Maria Patterson
Manchester (Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and 
Central Manchester University Hospitals NHS Foundation Trust): Natalie Arran; Jenny Callaghan; David Craufurd; 
Ruth Fullam; Liz Howard; Susan Huson; Emma Oughton; Lucy Partington-Jones;); Julie Snowden; Andrea Sollom; 
Cheryl Stopford; Jennifer Thompson; Iris Trender-Gerhad; Nichola Verstraelen (formerly Ritchie); Leann 
Westmoreland
Sheffield (The Royal Hallamshire Hospital): Oliver Bandmann; Alyson Bradbury, Paul Gill, Helen Fairtlough, Kay 
Fillingham, Isabella Foustanos; Kirsty O’Donovan; Nadia Peppa, Katherine Tidswell, Oliver Quarrell 
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